| cerlapirdine (PF-5212365) / Pfizer |
NCT00479297: Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Japanese Males |
|
|
| Completed | 1 | 72 | Japan | SAM-531 | Wyeth is now a wholly owned subsidiary of Pfizer | Alzheimer Disease | 02/07 | 02/07 | | |
NCT00479349: Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of SAM-531 |
|
|
| Completed | 1 | 32 | Japan | SAM-531 | Wyeth is now a wholly owned subsidiary of Pfizer | Alzheimer Disease | 01/08 | 01/08 | | |
NCT00745576: Study Evaluating The Potential Interaction Between Verapamil Immediate Release And SAM-531 When Co-Administered |
|
|
| Completed | 1 | 14 | Europe | SAM-531 | Wyeth is now a wholly owned subsidiary of Pfizer | Alzheimer Disease | 12/08 | 12/08 | | |
NCT00726115: Study Evaluating Safety, Tolerability and Pharmacokinetics of Single and Multiple Dose of SAM-531 |
|
|
| Completed | 1 | 56 | Europe | SAM-531, placebo | Wyeth is now a wholly owned subsidiary of Pfizer | Alzheimer Disease | 02/09 | 02/09 | | |
NCT00906191: Study Evaluating How Quickly And To What Extent The 14-Carbon-SAM-531 Is Absorbed/Converted/Eliminated In Male Subjects |
|
|
| Completed | 1 | 6 | Europe | SAM-531 | Wyeth is now a wholly owned subsidiary of Pfizer | Alzheimer Disease | 08/09 | 08/09 | | |
NCT00966966: Study Evaluating Potential Interaction Between SAM-531 And Gemfibrozil When Co-Administered |
|
|
| Completed | 1 | 17 | Europe | SAM-531 and gemfibrozil | Wyeth is now a wholly owned subsidiary of Pfizer, Pfizer | Healthy | 12/09 | 12/09 | | |
